Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

Photoageing

Also known as: photoaging, sun-related skin ageing, photodamage, dermatoheliosis

Photoageing is the gradual change in skin caused by repeated exposure to ultraviolet light, mainly from the sun. It can produce uneven colour, lines, roughness and altered elasticity, especially on exposed areas, alongside the changes that happen naturally with age.

In plain English — Photoageing is the effect that repeated sun exposure has on the skin over time, including lines, uneven colour and changes in texture. Sun protection can help limit further changes, and some treatments can improve particular visible signs. A new or changing patch needs assessment before it is treated as an appearance concern.

Evidence status

Strong

Human research supports ultraviolet exposure as a cause of photoageing, with randomised evidence for sunscreen prevention and particular tretinoin formulations for visible facial signs. Effect sizes and safety findings belong to the measured outcome, population and product; darker skin is underrepresented in much of the clinical evidence.

What photoageing is, and the patterns seen#

Photoageing is the cumulative effect of ultraviolet exposure on skin. It develops alongside intrinsic ageing, which also affects protected areas. Common exposed sites include the face, neck, arms and hands. Lines, irregular pigmentation, roughness, altered elasticity and visible small vessels can occur in varying combinations.[1, 8]

Marked photodamage can look coarse and leathery, or relatively smooth, thin and vascular. These are often described as hypertrophic and atrophic patterns. Skin tone, exposure history and individual susceptibility affect the presentation. A wrinkle score therefore captures only one part of the picture.[1, 7]i

Use of photoageing in aesthetic practice#

The term helps organise a consultation around sun exposure, present skin changes and the client’s priorities. It separates three purposes: preventing further exposure, improving selected visible signs and identifying lesions needing medical care.[1, 2, 7]i

What follows covers recognition and the overall choice of care. See sunscreen and SPF for protection labelling, retinoids for distinctions between vitamin-A ingredients and medicines, and hyperpigmentation for the pigment differential. Procedure-specific guidance appears with the relevant treatment, including the chemical-peel guide.

Contraindications and cautions#

Suitability concerns the proposed intervention, rather than photoageing as a diagnosis. Pregnancy and planned pregnancy are particularly important when a topical retinoid medicine is considered: MHRA advice excludes its use as a precaution because fetal risk cannot be ruled out, despite low expected systemic exposure. This is distinct from oral retinoid pregnancy-prevention requirements.[6]

Current medicines, product reactions and recent procedures belong in assessment of the chosen treatment. Individual product information and the treating clinician’s assessment determine suitability; a general photoageing label cannot supply that decision. The referral section below sets out the changes requiring assessment before elective work.

Clinical uses and the evidence behind them#

Prevention of further change

The Nambour randomised trial supports a preventive role for regular sunscreen. Among 903 age-eligible Australian participants younger than 55, 886 contributed usable hand-surface measurements and 604 had paired measurements. Allocation to daily use of one broad-spectrum SPF15+ product produced less progression than discretionary use over 4.5 years. Participants were predominantly fair-skinned. Funding included the Australian NHMRC, sunscreen manufacturer Ross Cosmetics and Roche; the authors reported no funder role in study or publication decisions.[3]

Improvement in established visible signs

A 2025 meta-analysis of eight vehicle-controlled facial trials, involving 1361 people over 16 weeks to two years, found greater improvement with tretinoin in fine wrinkles (mean difference 0.412; 95% CI 0.233–0.590) and, across six trials, coarse wrinkles (0.245; 95% CI 0.119–0.370). These are pooled study-scale results, not percentages of wrinkles removed. Fine-wrinkle results showed potential publication bias; all included trials listed commercial support, although the review itself declared none.[4]

One OrthoNeutrogena-supported trial treated 204 people with moderate-to-severe facial photodamage for up to two years. The studied 0.05% tretinoin emollient cream improved investigator-rated wrinkles, mottled pigmentation, lentigines and sallowness more than vehicle. Several authors had manufacturer employment, equity or consultancy interests. This supports that medicine and formulation, rather than every retinol-containing cosmetic.[5]i

Supportive and targeted care

Moisturisers can improve dry, flaky skin. Resurfacing, vascular treatment and other appearance-focused interventions address different features and have their own evidence and safety requirements. A treatment selected for surface texture is not automatically the appropriate choice for a blood vessel, a discrete pigmented lesion or laxity.[1, 2, 7]i

Selecting care for photoageing#

Selection starts with the feature that matters to the client: discomfort or dryness, texture, lines, colour, vessels or laxity. The assessment also considers whether the change is diffuse or a distinct lesion and whether it is stable or evolving. This links an appearance goal to an appropriate assessment or intervention, rather than treating all visible ageing as one target.[1, 7]i

For prevention, NHS advice combines shade and protective clothing with sunscreen of at least SPF30 and UVA protection. UV tanning adds exposure associated with premature ageing. Practical protection depends on exposure and sun response; the sunscreen entry covers selection and labelling in detail.[2]

For improvement, the useful comparison is the actual formulation or procedure, measured outcome and relevant population. The retinoid entry explains the cosmetic-versus-medicine distinction without turning study regimens into instructions.

Adverse effects and their management#

Topical treatment reactions

Tretinoin trials reported dryness, redness, peeling, burning and stinging. The pooled odds ratio for adverse events versus vehicle was 3.140 (95% CI 1.819–5.419), with substantial between-study variability (I² 73.3%). This is an odds comparison, not an individual patient’s probability. Tolerance and product choice need review when reactions disrupt comfortable use; the prescription and its clinical oversight govern any adjustment.[4]

Procedure-related effects

Resurfacing, injection and vascular procedures are different interventions. Their recovery expectations and complication pathways belong to the selected procedure’s assessment, consent and follow-up, rather than a generic photoageing aftercare routine. The linked treatment entries provide that context.[1, 2, 7]i

Acute sun injury

Sunburn is an acute injury alongside, rather than a measure of, cumulative photoageing. NHS advice calls for medical help when it is accompanied by feeling unwell, marked swelling or blistering.[2]

Referral and scope boundaries#

Actinic keratoses can feel like persistent rough or scaly patches and occur on exposed skin. They need medical identification: cosmetic roughness and a sun-damaged lesion cannot safely be treated as interchangeable. NHS guidance advises GP assessment of new patches, particularly those that grow, bleed, change colour, become tender or form a lump, and patches on the lips.[2, 7]i

A new growth, or a mole or patch changing in size, shape or colour, also warrants prompt medical assessment. Cosmetic treatment of that area should await assessment; appearance improvement is a separate task from deciding what the lesion is.[2, 7]i

Mechanism of action#

UV exposure can change the balance of formation and breakdown in the dermal matrix, the supporting material around skin cells. In human experiments involving subsets of 59 white adults aged 21–58, researchers exposed buttock skin to UV and measured increases in matrix-degrading enzymes and collagen-breakdown products over hours to days. The study received Johnson & Johnson support and disclosed relevant patent interests. It establishes a human biological response, not a long-term facial treatment result.[8]

In a separate repeated-exposure experiment, 12 people with lightly pigmented buttock skin received up to four daily UVA1 exposures. Matrix-metalloproteinase gene expression increased despite the skin becoming darker. This was a short-term molecular experiment; the paper reported grant support and no conflicts.[9]

Commonly misstated claims#

The percentage of ageing attributed to sunlight

Claim heard:Sunlight causes exactly 80% of everyone’s skin ageing.

Literature finding:The estimate is associated with a cross-sectional study of 298 white women aged 30–78 in Montpellier. Its calculation compared scores for selected sun-associated facial signs with scores for all assessed signs; several authors worked for L’Oréal or Biotherm.[10]i

Supported statement:The study supports the importance of sun exposure in that setting; its score ratio is not a universal causal percentage for every person’s skin ageing.[10]i

The sunscreen trial’s 24% figure

Claim heard: Sunscreen made participants look 24% younger.

Literature finding:The Nambour result was relative odds of 0.76 (95% CI 0.59–0.98) for progression in hand-surface grades.[3]i

Supported statement: The percentage expresses relative odds for that measured outcome, not a percentage reduction in facial wrinkles or biological age.[3]i

Complete reversal and the 100% improvement figure

Claim heard: A year of SPF30 completely reverses photodamage in everyone.

Literature finding:In a manufacturer-funded, before-and-after study of one SPF30 formulation, 33 participants enrolled and 32 completed 52 weeks of facial use. All completers improved on dermatologist-rated texture and clarity. Johnson & Johnson manufactured the formulation and employed three authors; other authors disclosed paid study, consultancy or writing roles.[11]i

Supported statement: That particular formulation was associated with improvements in those measures; the study did not establish complete recovery, improvement in every outcome for everyone or the same effect from every sunscreen.[11]i

Areas of remaining uncertainty#

  • Population coverage: prominent clinical datasets largely concern white or lighter-skinned participants; a precise treatment-effect estimate for an underrepresented population should therefore remain qualified.[3, 4, 5]i
  • Durability: treatment lasting up to two years is different from follow-up after treatment ends; expected persistence should therefore be discussed separately from the initial response.[3, 4, 5]i
  • Choice between approaches: studies use different outcomes, products and durations; the available comparisons therefore do not provide one treatment ranking for every combination of wrinkles, pigmentation, vessels and laxity.[3, 4, 5]i

Frequently asked questions#

What is the first useful distinction in a consultation?

Whether the concern is a stable, general appearance change or a particular lesion that needs assessment. The referral section lists the relevant changes; the distinction determines the next step.[2, 7]i

What does a client usually mean by sun damage?

Often a combination of uneven colour, lines or texture changes. Clarifying which feature they want addressed makes the goal more meaningful than an undifferentiated promise of rejuvenation.[1, 8]

Can care include both prevention and improvement?

Yes. Photoprotection addresses continuing exposure, while selected treatments may improve existing visible signs. Those are complementary purposes, assessed through different outcomes.[1, 2, 7]i

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. Ayer J. Skin ageing. DermNet. June 2018. Accessed 16 September 2026.Tier 4Supports: Clinical distinction between intrinsic ageing and photoageing, presentation, atrophic and hypertrophic phenotypes, and categories of supportive and procedural care. Expert educational review, not a systematic comparison.Funding / interest: No funding or author conflict statement was present in the retrieved educational page; independence is not assumed.
  2. NHS. Sunscreen and sun safety. Reviewed 24 March 2026. Accessed 16 September 2026.Tier 1Supports: Public advice on shade, clothing, SPF and UVA protection, avoidance of UV tanning, sunburn escalation and new or changing lesions. Not a procedure-licensing document.Funding / interest: NHS public-health guidance; no product sponsor or page-specific funding disclosure stated.
  3. Hughes MCB, Williams GM, Baker P, Green AC. Sunscreen and prevention of skin aging: a randomized trial. Annals of Internal Medicine. 2013;158(11):781–790. doi:10.7326/0003-4819-158-11-201306040-00002. PMID:23732711.Tier 2Supports: Nambour community trial: hand-surface microtopography over 4.5 years, with 903 age-eligible participants, 886 contributing usable data and 604 paired replicas. Table 4 and abstract give relative odds 0.76, 95% CI 0.59–0.98.Funding / interest: Australian NHMRC, Ross Cosmetics and Roche Vitamins and Fine Chemicals supported the study. The paper states that these funders had no role in design, conduct, analysis or manuscript decisions.
  4. Huang HY, Lee LTJ. Tretinoin for photodamaged facial skin: systematic review and meta-analysis of randomized controlled trials. Dermatology Practical & Conceptual. 2025;15(4):5172. doi:10.5826/dpc.1504a5172. PMID:41236273.Tier 1Supports: Eight vehicle-controlled facial studies, 1361 participants and 16 weeks to two years of treatment; improvement in fine/coarse wrinkles, increased irritation, publication-bias and generalisability limits. No GRADE certainty rating reported.Funding / interest: The review reports no funding or competing interests. Its Table 1 lists commercial support for each included trial, predominantly Johnson & Johnson group companies.
  5. Kang S, Bergfeld W, Gottlieb AB, et al. Long-term efficacy and safety of tretinoin emollient cream 0.05% in the treatment of photodamaged facial skin: a two-year, randomized, placebo-controlled trial. American Journal of Clinical Dermatology. 2005;6(4):245–253. doi:10.2165/00128071-200506040-00005. PMID:16060712.Tier 2Supports: 204 treated participants with moderate-to-severe facial photodamage, up to two years: specific formulation improved investigator-rated wrinkles and several pigment/colour outcomes versus vehicle.Funding / interest: Supported by OrthoNeutrogena. Grossman, Nyirady and Nighland were or had been Johnson & Johnson employees with equity; Savin held equity. Other named investigators disclosed research or consultancy relationships.
  6. Medicines and Healthcare products Regulatory Agency. Oral retinoid medicines: revised and simplified pregnancy prevention educational materials for healthcare professionals and women. Drug Safety Update. 19 June 2019; section on topical retinoids. Accessed 16 September 2026.Tier 1Supports: Topical retinoid medicines are contraindicated during pregnancy as a precaution and should not be used when planning pregnancy; this differs from oral-retinoid pregnancy-prevention requirements.Funding / interest: UK medicines-regulator safety communication; no product sponsor stated.
  7. NHS. Actinic keratoses (solar keratoses). Reviewed 14 June 2023. Accessed 16 September 2026.Tier 1Supports: Rough/scaly sun-damaged patches, potential progression, and GP assessment for new, growing, bleeding, changing, tender or lip lesions. The displayed next-review date had passed at access.Funding / interest: NHS patient guidance; no product sponsor or page-specific funding disclosure stated.
  8. Fisher GJ, Wang ZQ, Datta SC, Varani J, Kang S, Voorhees JJ. Pathophysiology of premature skin aging induced by ultraviolet light. New England Journal of Medicine. 1997;337(20):1419–1428. doi:10.1056/NEJM199711133372003. PMID:9358139.Tier 3Supports: Human in-vivo UV experiments on buttock skin of 59 white adults across substudies; short-term matrix metalloproteinase induction and collagen-breakdown measurements, not long-term facial treatment outcomes.Funding / interest: Babcock Endowment, Dermatology Foundation and Johnson & Johnson grants. Fisher and Voorhees, and Kang on a pending application, disclosed relevant patent interests with potential future royalties.
  9. Wang F, Smith NR, Tran BAP, Kang S, Voorhees JJ, Fisher GJ. Dermal damage promoted by repeated low-level UV-A1 exposure despite tanning response in human skin. JAMA Dermatology. 2014;150(4):401–406. doi:10.1001/jamadermatol.2013.8417. PMID:24305962.Tier 3Supports: Short-term human buttock-skin UVA1 experiments: repeated-exposure substudy n=12, lightly pigmented skin, gene-expression outcomes despite increasing pigmentation.Funding / interest: Grants AG025186 and AR048077 reported. Authors declared no financial disclosure or conflict of interest in this paper; the distinct disclosure in Fisher 1997 is not silently transferred or erased.
  10. Flament F, Bazin R, Laquieze S, Rubert V, Simonpietri E, Piot B. Effect of the sun on visible clinical signs of aging in Caucasian skin. Clinical, Cosmetic and Investigational Dermatology. 2013;6:221–232. doi:10.2147/CCID.S44686. PMID:24101874.Tier 3Supports: Cross-sectional facial scoring in 298 white women aged 30–78 in Montpellier; origin and scope of the paper's approximately 80% estimate.Funding / interest: Several authors were affiliated with L'Oréal Research and Innovation or Biotherm. The paper nevertheless declares no conflicts; no separate explicit funding statement was located in the retrieved full text.
  11. Randhawa M, Wang S, Leyden JJ, Cula GO, Pagnoni A, Southall MD. Daily use of a facial broad spectrum sunscreen over one-year significantly improves clinical evaluation of photoaging. Dermatologic Surgery. 2016;42(12):1354–1361. doi:10.1097/DSS.0000000000000879. PMID:27749441.Tier 3Supports: One SPF30 formulation, facial before-and-after assessment over 52 weeks; 33 enrolled and 32 completed. The 100% figure concerns improvement in texture and clarity among completers, not complete reversal of photodamage.Funding / interest: Johnson & Johnson funded the study and manufactured the tested formulation; Randhawa, Cula and Southall were employees. Other authors disclosed consultancy or compensated study/writing roles.